P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS

P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS

Bibliographic Details
Main Authors:	U. Pakulska, N. Angelosanto, M. Mikula, H. Nogai, R. Dudziak, C. Abboud, M. Obacz, K. Goller, M. Cybulska, M. Mazan, M. Kozakowska, T. Rzymski
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844688.25652.68

Similar Items

P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE
by: C. Abboud, et al.
Published: (2022-06-01)

Inherited predisposition to MDS/AML
by: Ana Rio Machin, et al.
Published: (2018-06-01)

Alignment of RVU Targets With Operating Room Block Time
by: Saieesh A. Rao, MD, et al.
Published: (2023-03-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
by: Barbara De Moerloose
Published: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
by: Theilgaard-Mönch, K, et al.
Published: (2011)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
by: Zachary Zaroogian, et al.
Published: (2023-08-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
by: V. Van Oorschot, et al.
Published: (2022-06-01)

Telomere length is an independent prognostic marker in MDS but not in de novo AML
by: Williams, J, et al.
Published: (2017)

P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA
by: Ewa Lech-Marańda, et al.
Published: (2023-08-01)

p53 biology and reactivation for improved therapy in MDS and AML
by: Joanna E. Zawacka
Published: (2024-03-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
by: A. G. Lema Fernandez, et al.
Published: (2022-06-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
by: V. Sheth, et al.
Published: (2022-06-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
by: YE Xiangjun, LU Xingguo
Published: (2023-10-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
by: Christoforos K. Vaxevanis, et al.
Published: (2023-12-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
by: Nadia El Menshawy, et al.
Published: (2020-07-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
by: Guancui Yang, et al.
Published: (2022-10-01)

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations
by: Jiuwei Lu, et al.
Published: (2024-04-01)

DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A
by: Ying Yang, et al.
Published: (2021-05-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
by: A. Shastri, et al.
Published: (2024-01-01)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
by: Anson Snow, et al.
Published: (2022-07-01)

CDK6 Inhibition: A Novel Approach in AML Management
by: Iris Z. Uras, et al.
Published: (2020-04-01)

P471: ERYTHROID/MEGAKARYOCYTIC DIFFERENTIATION BIAS IN BONE MARROW OF AML/MDS PATIENTS AFTER DECITABINE TREATMENT
by: F. Tiso, et al.
Published: (2022-06-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

VENETOCLAX-BASED THERAPIES IN PEDIATRIC ADVANCED MDS AND RELAPSED/REFRACTORY AML: A MULTICENTER RETROSPECTIVE ANALYSIS
by: Riccardo Masetti, et al.
Published: (2023-12-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
by: Sandra Huber, et al.
Published: (2023-08-01)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
by: Anne Sophie Kubasch, et al.
Published: (2018-05-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
by: Tahsin Anwar, et al.
Published: (2023-12-01)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7
by: Hiroyoshi Kunimoto, et al.
Published: (2020-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
by: Barreyro, L, et al.
Published: (2012)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
by: Hongjiao Li, et al.
Published: (2023-11-01)

RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with <i>DNMT3A</i> Mutations
by: Olga Alexandra Sidorova, et al.
Published: (2022-03-01)

Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling
by: Cheonghwa Lee, et al.
Published: (2023-11-01)

P411: SF3B1 MUTATIONS IN AML ARE STRONGLY ASSOCIATED WITH MECOM REARRANGEMENTS AND MAY BE INDICATIVE OF AN MDS PRE-PHASE
by: S. Huber, et al.
Published: (2022-06-01)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
by: Ecmel Mehmetbeyoglu, et al.
Published: (2023-08-01)

Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells
by: Qiwei Wang, et al.
Published: (2022-09-01)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
by: Jeroen Janssen, et al.
Published: (2021-02-01)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry
by: Daniel A. Pollyea, et al.
Published: (2020-07-01)